Steven Berry
Optometrist · Albuquerque, NMNPI 1578538872
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.3% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Biotissue Holdings Inc. at 24.1% of the total. Reporting peaked in 2022 at $1,940 and has fallen 65.4% since, to $671 in 2025. Among optometrist clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $32.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$1K
- Alcon$833
- Johnson & Johnson Vision Care, Inc.$581
- Bausch & Lomb Americas Inc.$454
- Dompe US, Inc.$434
- Sun Pharmaceutical Industries Inc.$366
- plus $2K from 14 others
What the payments were for
- Travel & lodging$2174%
- Food & beverage$5,35395%
- Education$281%
- Entertainment$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 27 | $1,352 |
| Alcon | 20 | $833 |
| Johnson & Johnson Vision Care, Inc. | 22 | $581 |
| Bausch & Lomb Americas Inc. | 15 | $454 |
| Dompe US, Inc. | 14 | $434 |
| Sun Pharmaceutical Industries Inc. | 14 | $366 |
| AbbVie(2 entities) | 12 | $312 |
| Coopervision Inc. | 11 | $230 |
| Sight Sciences, Inc. | 2 | $222 |
| Shire North American Group Inc | 7 | $201 |
| Novartis | 7 | $118 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $112 |
| Apellis Pharmaceuticals, Inc. | 1 | $109 |
| Mallinckrodt Hospital Products Inc. | 5 | $97 |
| Kala Pharmaceuticals, Inc. | 2 | $96 |
| Harrow Eye, LLC | 1 | $26 |
| Maculogix, Inc. | 1 | $26 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Optos, Inc. | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$801
- AmnioGraft$801
- Oxervate$237
- Acuvue$224
- TRYPTYR$147
- MIEBO$125
- XIIDRA$125
- CEQUA$125
- OMNI(R) SURGICAL SYSTEM (US)$114
- Syfovre$109
- TearCare SmartLid$108
- TEARCARE(TM) (2.2) SYSTEM KIT$108
- VUITY$101
How this compares
$5,615 in reported general payments places this provider in the 95th percentile of 228 optometrist providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 30 | $27,675 |
| LumiganBimatoprost | 37 | $18,842 |
| XiidraLifitegrast | 13 | $17,263 |
| RestasisCyclosporine | 12 | $14,133 |
| TyrvayaVarenicline Tartrate | 18 | $11,488 |
| Restasis MultidoseCyclosporine | 14 | $10,043 |
| Loteprednol Etabonate | 30 | $4,578 |
| Prednisolone Acetate | 27 | $1,456 |
| Latanoprost | 32 | $983 |
| Doxycycline Hyclate | 13 | $450 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 17 | $224 |
| Ofloxacin | 18 | $208 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 16 | $139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $454 | $44,93943 claims |
| AbbVieLumigan, Restasis, Restasis Multidose | $312 | $43,01863 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $112 | $4,57830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 228 optometrist providers in New Mexico.
Other optometrist in Albuquerque
- David BabingtonAlbuquerque$8K
- Nicolette EstradaAlbuquerque$6K
- Vanessa ChavezAlbuquerque$5K
- Mamie ChanAlbuquerque$5K
- Alissa IronsAlbuquerque$4K
- Melynda TorresAlbuquerque$4K
- Robert LavoieAlbuquerque$4K
- Lauren ByingtonAlbuquerque$3K
- David MagnusAlbuquerque$3K
- Frank ChinisciAlbuquerque$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.